2890688-86-3
Chemical Structure
Mosnodenvir
Synonym(s): JNJ-1802
- CAS No.: 2890688-86-3
- Formula:C26H22ClF3N2O6S
- Molecular Weight:582.98
InChIKey: QNOPDDHSGQQLCV-UHFFFAOYSA-N
SMILES: CS(C1=CC(OC)=CC(N[C@@H](C2=C(C=C(C=C2)Cl)OC)C(C(C3=C4)=CNC3=CC=C4OC(F)(F)F)=O)=C1)(=O)=O
Biological Activity: Mosnodenvir (JNJ-1802) is an orally active pan serotype dengue virus (DENV) inhibitor, with EC50 values ranging from 0.057 to 11 nM for four dengue virus (DENV) serotypes. Mosnodenvir blocks viral replication by inhibiting the formation of complexes between two viral proteins, nonstructural protein 3 (NS3) and NS4B, thereby preventing the formation of new viral RNA. Mosnodenvir exhibits picomolar to nanomolar antiviral activity in vitro and has antiviral efficacy in mice and non-human primates[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Mosnodenvir | 99.77% | Mosnodenvir (JNJ-1802) is an orally active pan serotype dengue virus (DENV) inhibitor, with EC50 values ranging from 0.057 to 11 nM for four dengue virus (DENV) serotypes. Mosnodenvir blocks viral replication by inhibiting the formation of complexes between two viral proteins, nonstructural protein 3 (NS3) and NS4B, thereby preventing the formation of new viral RNA. Mosnodenvir exhibits picomolar to nanomolar antiviral activity in vitro and has antiviral efficacy in mice and non-human primates. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 1.00
HY-182317(+)-Mosnodenvir -
Similarity Score 0.50
HY-138061DENV-IN-2 -
Similarity Score 0.47
HY-170933SGK1-IN-6 -
Similarity Score 0.47
HY-156332TNKS-2-IN-2 -
Similarity Score 0.47
HY-70069RGSK256066 Trifluoroacetate (Standard) -
Similarity Score 0.46
HY-135081N-(4-acetamidophenyl)-Indomethacin amide -
Similarity Score 0.45
HY-10469RGSK256066 (Standard) -
Similarity Score 0.45
HY-155249KGP591 -
Similarity Score 0.45
HY-142703RORγt inverse agonist 28 -
Explore the MedChemAI to find more analogs
References
- [1]. Ackaert O, et al. Safety, tolerability and pharmacokinetics of JNJ-1802, a pan-serotype dengue direct antiviral small molecule, in a Phase 1, double-blind, randomized, dose-escalation study in healthy volunteers. Clin Infect Dis. 2023 May 10:ciad284. [Content Brief]
- [2]. Goethals O, et al. Blocking NS3-NS4B interaction inhibits dengue virus in non-human primates. Nature. 2023 Mar;615(7953):678-686. [Content Brief]
